



Public Formulary Overview – Prince Edward Island

December 2021

Formulation	Trade Name	Coverage
Long-Acting Stimulants	Adderall XR	Covered – No Restrictions
	Biphentin – 1 mg/kg/day 80mg maximum	Special Authorization
	Concerta – Dosing per CCP* MPH ER / ER-C – Dosing per CCP*	
	Vyvanse – 60 mg max For treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years and older who: <ul style="list-style-type: none">• Have experienced unsatisfactory results due to poor symptom control, side effects, administrative barriers and/or societal barriers.• AND Have been tried on methylphenidate (immediate release or long-acting formulation) or dexamphetamine (immediate release or long-acting formulation) with unsatisfactory results. Must be prescribed or recommended by a pediatrician, psychiatrist, or general practitioner with expertise in the treatment of ADHD. Refer to the maximum billable dose as indicated. Concurrent use of long acting formulations of drugs for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) will not be approved	
	Foquest	Not Covered
Short Acting Stimulants	Ritalin Ritalin SR Dexedrine Dexedrine Spansules	Covered – No Restrictions
Non-Stimulant Medications	Strattera	Covered – No Restrictions
	Intuniv XR	Not Covered

Information retrieved from the province of Prince Edward Island in December 2021, [click here](#) to access the most up to date coverage information. [Special Authorization](#) form must be submitted when applicable. for more information on special authorization, [click here](#).